항균제 내성 감시 시장 규모, 점유율, 성장 분석 : 컴포넌트별, 기술별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Antimicrobial Resistance Surveillance Market size was valued at USD 6.23 Billion in 2024 and is poised to grow from USD 6.58 Billion in 2025 to USD 10.17 Billion by 2033, growing at a CAGR of 5.6% during the forecast period (2026-2033).

The escalating prevalence of antimicrobial resistance poses significant global health threats, prompting a coalition of governments, health organizations, and intergovernmental bodies to enhance surveillance systems. There is an increasing demand for real-time data collection, pathogen tracking, and resistance pattern analysis as drug-resistant infections rise, highlighting the necessity for sophisticated antimicrobial resistance surveillance solutions. This heightened emphasis on public health readiness and infection management is substantially propelling market expansion. In tandem, regulatory standards and international initiatives are driving the enhancement of surveillance capabilities. Many nations are investing in laboratory infrastructure, integrated data platforms, and immediate data reporting tools to strengthen these surveillances. Healthcare providers are leveraging these advancements to align with infection control protocols, thereby promoting antimicrobial stewardship and reducing healthcare-related infections, paving the way for sustained market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antimicrobial Resistance Surveillance market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antimicrobial Resistance Surveillance Market Segments Analysis

Global Antimicrobial Resistance Surveillance Market is segmented by Component, Technology, End User and region. Based on Component, the market is segmented into Software, Hardware and Services. Based on Technology, the market is segmented into Phenotypic Methods, Genotypic Methods and Bioinformatics Solutions. Based on End User, the market is segmented into Hospitals and Clinics, Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes and Public Health Agencies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antimicrobial Resistance Surveillance Market

The escalating prevalence of drug-resistant infections has emerged as a serious global public health concern. The surge in resistance rates has prompted federal and health organizations to develop sophisticated surveillance systems capable of detecting resistance patterns in real-time, facilitating prompt response measures. As both national and local governments recognize the critical need for enhanced antimicrobial resistance surveillance, there is a concerted effort to avert outbreaks, minimize treatment failures, and support the formation of national health policies. This heightened awareness and demand for effective monitoring solutions are key factors driving the growth of the global antimicrobial resistance surveillance market.

Restraints in the Global Antimicrobial Resistance Surveillance Market

The development of an effective antimicrobial resistance surveillance system is hindered by substantial financial requirements for laboratory infrastructure, data integration technologies, and the training of skilled personnel. This challenge is particularly pronounced in lower-income nations, where resources are often limited. Moreover, the expensive nature of analyzing surveillance data through genomic methods further restricts the reach and implementation of global antimicrobial resistance surveillance initiatives. These financial and operational barriers collectively impede progress and limit the potential growth of the market, highlighting the need for targeted investments and international collaboration to enhance surveillance capabilities worldwide.

Market Trends of the Global Antimicrobial Resistance Surveillance Market

The Global Antimicrobial Resistance Surveillance market is experiencing a notable trend of integrating artificial intelligence (AI) with genomic surveillance methodologies. This convergence of advanced AI platforms with whole-genome sequencing and bioinformatics is revolutionizing the detection of resistance genes, thus facilitating more precise and timely identification of antimicrobial threats. This technological synergy not only enhances the ability of healthcare systems to provide real-time alerts during outbreaks but also significantly strengthens predictive modeling, ultimately leading to more effective intervention strategies. As a result, the surveillance capabilities of healthcare systems globally are being substantially improved, fostering proactive measures against antimicrobial resistance.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Antimicrobial Resistance Surveillance Market Size by Component & CAGR (2026-2033)

• Market Overview
• Software
• Hardware
• Services

Global Antimicrobial Resistance Surveillance Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Phenotypic Methods
• Genotypic Methods
• Bioinformatics Solutions

Global Antimicrobial Resistance Surveillance Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals and Clinics
• Diagnostic Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Public Health Agencies

Global Antimicrobial Resistance Surveillance Market Size & CAGR (2026-2033)

• North America (Component, Technology, End User)
  • US
  • Canada
• Europe (Component, Technology, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Component, Technology, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Component, Technology, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Component, Technology, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BD (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OpGen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luminex Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accelerate Diagnostics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bruker Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QuantuMDx Group Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ArcBio LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bugworks Research Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations